

Supplementary Table 1. Baseline and longitudinal follow-up assessments schedule of KBASE cohort

Visit	Scr	BL	FU1	FU2	FU3	FU4
Informed Consent	X					
Inclusion/Exclusion Criteria	X					
Clinical Assessment (I)	X		X	X	X	X
Clinical Assessment (II)		O		O		O
Neuropsychological Assessment (I)	X		X	X	X	X
Neuropsychological Assessment (II)		O		O		O
Lifetime Experience and Personality Questionnaires		O		O		O
PET-MRI (FDG-PET)		O		O		O
PET-MRI (PiB-PET)		O		O		O
PET-CT (AV1451-PET)*				O		O
Blood Sampling		O		O		O
APOE Genotyping		O				
Basic Laboratory Tests		O		O		O
Actigraphy Application		O		O		O

*AV1451 PET will be applied to 210 participants. Scr: screening protocol, BL: baseline protocol, FU1: 1st follow-up, FU2: 2nd follow-up, FU3: 3rd follow-up, FU4: 4th follow-up, X: conducted at each clinical site, O: conducted at SHUH, PET: positron emission tomography, MRI: magnetic resonance image, FDG: fluorodeoxyglucose, PiB: Pittsburgh Compound B, APOE: apolipoprotein E